Scotia strategist updates his list of quantitatively-driven top Canadian stock picks
Tickers mentioned in this story
Study and track financial data on any traded entity: click to open the full quote page. Data updated as of 02/06/25 4:00pm EDT.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
29 minutes ago
- Globe and Mail
RouteGenie Announces Inside the Lamp Live 2025: A Must-Attend Event for NEMT Professionals
RouteGenie, a leading provider of Non-Emergency Medical Transportation (NEMT) software solutions, has officially announced the return of Inside the Lamp Live for 2025. The two-day event will take place August 22–23, 2025, at the Sheraton Suites Market Center Dallas. Designed as a high-impact forum for NEMT business owners, operations teams, and industry leaders, Inside the Lamp Live has quickly become one of the most anticipated gatherings in the NEMT space. Following the success of last year's inaugural event, Inside the Lamp Live 2025 will feature educational sessions, peer-led discussions, and product-focused workshops tailored to the real-world needs of NEMT professionals. The event will also provide an opportunity to connect with fellow transportation providers from across the country to share best practices and business strategies. The timing of the event is especially strategic, as it takes place just before the NEMTAC Transform 2025 Annual Conference, held at the Hilton Anatole—directly across the street from the Sheraton Suites venue. This gives attendees the unique advantage of participating in both events during a single trip to Dallas. 'This isn't just a software conference—it's a platform where transportation providers can engage, grow, and redefine how they operate,' said Yurii Martynov, Marketing Director at RouteGenie. 'Inside the Lamp Live is about more than RouteGenie. It's about helping the entire industry collaborate and thrive.' Inside the Lamp Live 2025 will cover a wide range of topics, including operational efficiency, compliance, staff training, dispatch management, billing optimization, and the latest RouteGenie feature updates. The event is open to both current RouteGenie users and NEMT companies exploring new technology solutions. Registration is now open on Eventbrite: Long-time RouteGenie customers and a transportation provider exploring new solutions, Inside the Lamp Live offers an unmatched opportunity to grow, learn, and prepare for what's next in NEMT. About RouteGenie: RouteGenie is the premier software solution for Non-Emergency Medical Transportation providers. Built by industry experts, RouteGenie automates dispatching, routing, and billing to help transportation companies run smarter, scale faster, and serve better. To learn more about the software, please request an NEMT software demo. Media Contact Company Name: RouteGenie Contact Person: Yurii Martynov Email: Send Email Country: United States Website:
Globe and Mail
29 minutes ago
- Globe and Mail
Zacks Earnings Trends Highlights: JPMorgan, Wells Fargo and Citigroup
For Immediate Release Chicago, IL – July 3, 2025– Zacks Director of Research Sheraz Mian says, "While negative revisions to Q2 estimates have stabilized in recent weeks, estimates for the period have been under significant pressure relative to other recent periods since the June-quarter got underway." Looking Ahead to Q2 Bank Earnings Note: The following is an excerpt from this week's Earnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please click here>>> Here are the key points: Total S&P 500 earnings for the June quarter are expected to be up +5.0% from the same period last year on +4.0% higher revenues. While negative revisions to Q2 estimates have stabilized in recent weeks, estimates for the period have been under significant pressure relative to other recent periods since the June-quarter got underway. Q2 earnings estimates for 13 of the 16 Zacks sectors have come down since the quarter got underway, with Aerospace, Utilities, and Consumer Discretionary as the only sectors whose estimates have modestly moved higher since the start of April. Q2 earnings estimates for the Tech and Finance sectors, the two largest contributors to aggregate S&P 500 earnings, accounting for 51% of all index earnings, have also been cut since the quarter got underway. The quarter started with significant pressure on Tech sector estimates, but the negative revisions trend notably stabilized in the subsequent weeks. In terms of year-over-year growth, three sectors are expected to enjoy double-digit earnings growth in Q2: Aerospace (+15.2%), Tech (+12.1%), and Consumer Discretionary (+106.1%). On the negative side, seven sectors are expected to earn less in Q2 relative to the year-earlier period, with double-digit declines at the Energy (-25.7%), Construction (-14.7%), and Autos (-31.2%) sectors. Bank Earnings in Focus JPMorgan JPM, Wells Fargo WFC and Citigroup C will kick-start the June-quarter reporting cycle for the Finance sector on July 15 th. These banks comfortably passed the Fed's stress tests, opening the way for increased capital returns to shareholders through share buybacks and dividend hikes. However, the earnings outlook for the group remains subdued, with growth hindered by weak demand trends in both the conventional banking business and investment banking. For JPMorgan, Q2 earnings are expected to be down -5.6% on -13.4% lower revenues. For Citigroup and Wells Fargo, Q2 earnings are expected to be down -3.2% and -6.8% from the year-earlier level, respectively. The Zacks Investment Brokers & Managers industry at the mezzanine level, which includes JPMorgan, Citigroup, and Wells Fargo, total Q2 earnings are expected to be down -2.8% from the same period last year, on -0.6% lower revenues. For the Zacks Finance sector, Q2 earnings are expected to be up +8.2% on +3.9% higher revenues. Unlike the group's anemic earnings growth expectations, these stocks have been standout performers in the market lately, which likely reflects the aforementioned capital returns expectations and hopes of improving earnings growth in the coming periods. Expectations for 2025 Q2 The start of Q2 coincided with heightened tariff uncertainty following the punitive April 2 nd tariff announcements. While the onset of the announced levies was eventually delayed by three months, the issue has understandably weighed heavily on estimates for the current and upcoming quarters, particularly in the first few weeks following the April 2 nd announcement. The expectation at present is for Q2 earnings for the S&P 500 index to increase by +5.0% from the same period last year on +4.0% higher revenues. While it is not unusual for estimates to be adjusted lower, the magnitude and breadth of Q2 estimate cuts are greater than we have seen in the comparable periods of other recent quarters. Since the start of the quarter, estimates have come down for 13 of the 16 Zacks sectors, with the biggest declines for the Transportation, Autos, Energy, Construction, and Basic Materials sectors. The only sectors experiencing favorable revisions in this period are Aerospace, Utilities, and Consumer Discretionary. Estimates for the two largest earnings contributors to the index – Tech & Finance – have also declined since the quarter began. Tech sector earnings are expected to be up +12.1% in Q2 on +10.9% higher revenues. While these earnings growth expectations are materially below where they stood at the start of April, the revisions trend appears to have notably stabilized lately, as we have been flagging in recent weeks. This stabilizing turn in the Tech sector's revisions trend can be seen in expectations for full-year 2025 as well. The two charts above show that estimates for the Tech sector have stabilized and are no longer under the type of downward pressure experienced earlier in the quarter. The Tech sector is much more than just any other sector, as it alone accounts for almost a third of all S&P 500 earnings. The Earnings Big Picture The market's rebound from the post-tariffs April lows has been very impressive, likely suggesting that market participants don't see the tariff uncertainty as presenting a significant threat. We find ourselves a bit skeptical of this sanguine view. Whatever the final level of tariffs turns out to be, it will have an impact on the earnings picture. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Follow us on Twitter: Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Wells Fargo & Company (WFC): Free Stock Analysis Report Citigroup Inc. (C): Free Stock Analysis Report
Globe and Mail
29 minutes ago
- Globe and Mail
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
While Eli Lilly 's LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — which accounted for 48% of overall sales in the first quarter of 2025. However, Lilly also boasts a wide range of products that serve other therapeutic areas, such as neuroscience, oncology and immunology — all high-growth areas and representing significant commercial potential. Some key growth products include the oncology drug Verzenio and immunology drug Taltz, which accounted for 9% and 6% of total first-quarter sales, respectively. Sales of these blockbuster medications are being driven by increased demand — Taltz sales rose 26% year over year during the quarter, while Verzenio sales jumped 10%. Over the past couple of years, LLY's new drugs — including Omvoh and Ebglyss in immunology, Jaypirca in oncology and Kisunla in neuroscience — have all been contributing to its top-line growth. Lilly expects the potential launch of new medicines like imlunestrant for metastatic breast cancer to contribute to growth in 2025. Though Lilly's non-obesity portfolio is contributing meaningfully, investor focus largely remains on the GLP-1 products. All eyes would be on the magnitude of their sequential growth and market share gains in the upcoming second-quarter results. Our model estimates sales at around $4.46 billion for Mounjaro and $3.09 billion for Zepbound in the to-be-reported quarter. Big Pharma Diversifies Beyond Flagship Drugs While Lilly's non-obesity portfolio is gaining traction, peers like AbbVie ABBV and Merck MRK are also broadening their therapeutic reach beyond core revenue drivers. AbbVie, which already markets multiple flagship immunology drugs — Humira, Rinvoq and Skyrizi — is expanding its presence in oncology and neuroscience. In recent years, ABBV has added Epkinly, Elahere and most recently, Emrelis, bringing its total oncology therapies to five. Growth in its neuroscience segment has also been supported by increasing uptake of its migraine drugs, Ubrelvy and Qulipta. Merck, whose flagship oncology drug Keytruda accounts for nearly half of its total revenues, is expanding its late-stage pipeline to reduce dependence on the product. We believe new products like Capvaxive (pneumococcal vaccine) and Winrevair (PAH drug) have the potential to generate significant revenues over the long term. Merck recently secured the FDA's approval for long-acting RSV antibody Enflonsia for newborns, which is expected to launch later this month. LLY's Price Performance, Valuation and Estimates Shares of Lilly have outperformed the industry year to date, as seen in the chart below. From a valuation standpoint, Eli Lilly is expensive. Based on the price/earnings (P/E) ratio, the company's shares currently trade at 29.45 times forward earnings, higher than its industry's average of 15.04. However, the stock is trading below its five-year mean of 34.54. Estimates for Lilly's 2025 EPS have declined from $22.23 to $21.95 in the past 60 days, and EPS estimates for 2026 have increased from $30.89 to $30.91 over the same timeframe. Eli Lilly currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report
